At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 83 enrolled
Drug / intervention
insulin glargine +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial
In Brief
A Phase 4 clinical trial evaluating insulin glargine, metformin, and 3 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 83 participants across 1 site.
Detailed Summary
The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada
CollaboratorsHamilton Health Sciences Corporation
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartJan 2011
Primary CompletionFeb 2015
Study CompletionSep 2015
TodayJul 2026
First PostedAug 13, 2010
Enrollment StartJan 1, 2011
Primary CompletionFeb 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 15.9 years ago
Interventions
insulin glarginedrug
sc injection
metformindrug
oral administration
acarbosedrug
oral administration
lifestyle therapybehavioral
diet and exercise
insulin glarginedrug
sc injection
metformindrug
oral administration
acarbosedrug
oral administration
lifestyle therapybehavioral
diet and exercise
Standard glycemic careother
as informed by the current clinical practice guidelines